Condition

Resectable Pancreatic Adenocarcinoma clinical trials and research

• 6Clinical trials
• 7Countries

Newest Resectable Pancreatic Adenocarcinoma clinical trials

All recruiting trials (6)

• ctDNA MRD monitoring during neoadjuvant treatment for pancreatic cancer

  We will see if regular blood tests for ctDNA (MRD) during neoadjuvant therapy can predict surgical success and longer survival for adults with borderline resectable or high‑risk resectable pancreatic cancer.

  Recruiting at 2 sites Ruijin Hospital · Shanghai and 1 other locations · NCT07080021

• Using NALIRIFOX for treating resectable pancreatic cancer before and after surgery

  This study is testing if a new combination treatment called NALIRIFOX can help people with resectable pancreatic cancer have better surgery results and live longer.

  Recruiting at 9 sites Phase 2 Taichung Veterans General Hospital · Kaohsiung City and 8 other locations · NCT06816914

• Evaluating the effects of oxaliplatin on liver and nerve toxicity in cancer patients

  This study is testing how the cancer drug oxaliplatin affects the liver and nerves in patients with pancreatic and esophageal cancers to help make chemotherapy safer and more effective.

  Recruiting University Hospital, Clermont-Ferrand · Clermont-Ferrand · NCT06649474

• Neoadjuvant chemotherapy for resectable pancreatic cancer

  This study is testing a combination of three chemotherapy drugs to see if it helps people with resectable pancreatic cancer get better before surgery.

  Recruiting Phase 2 Georgetown University · Washington D.C., District of Columbia and 1 other locations · NCT06423326

• Neoadjuvant treatment for borderline resectable pancreatic cancer

  This study is testing a new combination of chemotherapy, immunotherapy, and radiation before surgery to see if it can help people with borderline resectable pancreatic cancer live longer and have better treatment results.

  Recruiting at 3 sites Phase 1/2 Amsterdam UMC, location VUmc · Amsterdam and 3 other locations · NCT06384560

• Using Olaparib to Prevent Recurrence in Patients with Resected Pancreatic Cancer and Specific Genetic Mutations

  This study is testing if the drug olaparib can help prevent pancreatic cancer from coming back in patients who have had surgery and specific genetic mutations.

  Recruiting at 261 sites Phase 2 National Cancer Institute (NCI) · Anchorage, Alaska and 455 other locations · NCT04858334

Related topics

Quick answers

How many Resectable Pancreatic Adenocarcinoma clinical trials are recruiting right now?

6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 7 countries. The most sites are in United States (2 trials), Netherlands (1 trial), China (1 trial), Taiwan (1 trial), France (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 3, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →